Antineoplastic reduces relapse rate, delays disability progression in progressive MS

被引：0
|
作者：
不详
机构：
来源：
FORMULARY | 1998年 / 33卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：1170 / 1170
页数：1
相关论文
共 50 条
  • [31] Preventing progression and disability in MS—when to treat?
    Maura Pugliatti
    Nature Reviews Neurology, 2013, 9 : 129 - 130
  • [32] Teriflunomide reduces the Relapse Rate in Multiple Sclerosis
    Oberpichler-Schwenk, Heike
    Hess, Claudia
    Druckerei, W. Kohlhammer
    PSYCHOPHARMAKOTHERAPIE, 2011, 18 (06): : A1 - A2
  • [33] Multiple Sclerosis - Estriol reduces Relapse Rate
    Kilger, Ellen
    FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2016, 84 (03) : 131 - 131
  • [34] Therapy with Dimethyl fumarate reduces Relapse Rate
    Klein, Friederike
    FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2013, 81 (02) : 64 - 64
  • [35] Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data Network
    Lorscheider, Johannes
    Signori, Alessio
    Subramaniam, Suvitha
    Benkert, Pascal
    Vukusic, Sandra
    Trojano, Maria
    Hillert, Jan
    Glaser, Anna
    Hyde, Robert
    Spelman, Tim
    Magyari, Melinda
    Elberling, Frederik
    Pontieri, Luigi
    Koch-Henriksen, Nils
    Sorensen, Per Soelberg
    Gerlach, Oliver
    Prat, Alexandre
    Girard, Marc
    Eichau, Sara
    Grammond, Pierre
    Horakova, Dana
    Ramo-Tello, Cristina
    Roos, Izanne
    Buzzard, Katherine
    Scott, Jeanette Lechner
    Sanchez-Menoyo, Jose Luis
    Alroughani, Raed
    Prevost, Julie
    Kuhle, Jens
    Gray, Orla
    Mathey, Guillaume
    Michel, Laure
    Ciron, Jonathan
    De Seze, Jerome
    Maillart, Elisabeth
    Ruet, Aurelie
    Labauge, Pierre
    Zephir, Helene
    Kwiatkowski, Arnaud
    van der Walt, Anneke
    Kalincik, Tomas
    Butzkueven, Helmut
    Observatoire Francais de la Sclerose en Plaques OFSEP
    MSBase Study Group
    Swedish MS Registry
    Big MS Data Network
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2024,
  • [36] Modulation of Treatment Effect on Disability Progression by Disease Activity in Progressive MS: Insights from Individual Patient Data
    Montobbio, Noemi
    Bovis, Francesca
    Arnold, Douglas L.
    Sormani, Maria Pia
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 29 - 29
  • [37] Disability Improvement And Progression As Assessed By The Multiple Sclerosis Functional Composite In Progressive MS Patients From The Climb Study
    McAdams, M. T.
    Rosso, M.
    Healy, B. C.
    Yano, H.
    Glanz, B.
    Kern, R.
    Ward, S. E.
    Mehra, M.
    Weiner, H.
    Chitnis, T.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 150 - 151
  • [38] An adverse lipid profile is associated with disability and progression in disability, in people with MS
    Tettey, Prudence
    Simpson, Steve, Jr.
    Taylor, Bruce
    Blizzard, Leigh
    Ponsonby, Anne-Louise
    Dwyer, Terence
    Kostner, Karam
    van der Mei, Ingrid
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (13) : 1737 - 1744
  • [39] Active immunotherapy may delay disability in progressive MS
    Haghikia, Aiden
    Gold, Ralf
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2017, 88 (03): : 193 - 193
  • [40] Predictors of relapse rate in MS clinical trials
    Held, U
    Heigenhauser, L
    Shang, C
    Kappos, L
    Polman, C
    NEUROLOGY, 2005, 65 (11) : 1769 - 1773
12345